You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Details for Patent: 9,737,547


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 9,737,547 protect, and when does it expire?

Patent 9,737,547 protects BYFAVO and is included in one NDA.

This patent has twenty-one patent family members in sixteen countries.


Drugs Protected by US Patent 9,737,547

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Acacia BYFAVO remimazolam besylate POWDER;INTRAVENOUS 212295-001 Oct 6, 2020 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial USE OF REMIMAZOLAM FOR INDUCTION AND MAINTENANCE OF PROCEDURAL SEDATION IN ADULTS UNDERGOING PROCEDURES LASTING 30 MINUTES OR LESS ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 9,737,547

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
10014366Nov 8, 2010
10014784Nov 19, 2010
10014819Nov 22, 2010
10014972Nov 25, 2010
PCT Information
PCT FiledNovember 07, 2011PCT Application Number:PCT/EP2011/005581
PCT Publication Date:May 18, 2012PCT Publication Number: WO2012/062439

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.